Article info
PDFClinical/translational cancer immunotherapy
Original research
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
- Correspondence to Dr Christopher S Hourigan; hourigan{at}nih.gov
Citation
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
Publication history
- Accepted November 27, 2021
- First published January 11, 2022.
Online issue publication
October 18, 2023
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.